Skip to main content
. 2015 Oct 20;2015(10):CD010463. doi: 10.1002/14651858.CD010463.pub2

Quoix 2011b.

Methods Randomized phase III trial, multi‐center, open‐label
Inclusion criteria
  • 70 to 89 years of age, with cytologically or histologically confirmed non‐small cell lung cancer

  • Stage IV or III unsuitable for radical therapy

  • PS: 0 to 2, with adequate hematological, hepatic, and renal function and life expectancy ≥ 12 weeks

  • Previous radiation therapy at symptomatic sites if completed ≥ 3 weeks before inclusion

  • Asymptomatic brain metastases


Exclusion criteria
  • Active malignancy within past 5 years

  • Previous chemotherapy

  • Peripheral neuropathy ≥ grade 2

  • Co‐morbidities that impaired administration of chemotherapy or respiratory impairment that required long‐term oxygen delivery

Participants Monotherpy arm: 226
Doublet chemotherapy arm: 255
Baseline characteristics for intention‐to‐treat population: median age: 77.1 (range 70.0 to 88.8) years; 27.3% (123) ECOG of 2, 20.1% (88) with ADL score < 6, 15.2% (67) with MMSE < 23, 24.4% (110) with Charlson index > 2
Interventions Monotherapy arm: vinorelbine 25 mg/m2 i.v. infusion on days 1 and 8 or gemcitabine 1150 mg/m2 on days 1 and 8, every 3 weeks for maximum of 5 cycles
Doublet chemotherapy arm: carboplatin AUC6 i.v. infusion on day 1 plus paclitaxel 90 mg/m2 i.v. infusion on days 1, 8, and 15, every 4 weeks for maximum of 4 cycles
Primary prophylaxis with growth factor support not recommended, but secondary prophylaxis allowed for participants who developed grade 3 or 4 neutropenia in previous cycles
Outcomes Primary outcome
  • Overall survival (defined from date of randomization to death)


Secondary outcomes
  • Progression‐free survival (defined from date of randomization to disease progression or death, whichever occurred first)

  • Response at week 6

  • Toxicity (grades 3 and 4)

Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk "Randomisation was done centrally by computer. We used the minimisation method and stratified patients by study centre, WHO performance status score (0–1 vs 2), stage (III vs IV), and age (≤̀80 vs >80 years)"
Allocation concealment (selection bias) Unclear risk No information on allocation concealment
Blinding of outcome assessment (detection bias) 
 OS and 1y OS rate outcome Unclear risk Open‐label study considered to have unclear impact on mortality outcomes
Blinding of outcome assessment (detection bias) 
 Other outcomes High risk Response reviewed through investigator panels. No information on toxicity and quality of life assessments
Incomplete outcome data (attrition bias) 
 All outcomes Low risk Before the start of treatment, 1 participant excluded from the monotherapy and 2 from doublet chemotherapy group
Selective reporting (reporting bias) Low risk No evidence of selective reporting bias
Other bias Low risk No evidence of other bias